De la Llata M, Hálabe J, Plancarte R, Arrieta O, Burgos R, Campillo C, Celis MÁ, Domínguez J, Islas S, Jasso L, Lifshitz A, Moreno M, Reyes A, Ruiz-Argüelles G, Soda A, Verástegui E, Sotelo J

Language: Spanish
References: 0
Page: 534-536
PDF size: 121.53 Kb.

ABSTRACT

Several drugs with adequate efficacy have been withdrawn from the market for financial reasons, either due to their reduced price (the patent has expired) or because they have been substituted with new drugs (with patents in force); many others have not been developed because the diseases they are directed against are not economically promising owing to the type of population that suffers from them (economically marginalized or numerically non-significant strata). Guidelines and incentives for the pharmaceutical and biotechnological industry should be established.